CJC-1295 without DAC 20mg × 10 vials

A synthetic growth hormone-releasing hormone analogue studied for growth hormone signaling, pituitary response, IGF-1-related pathways, recovery research, body composition protocols, and broader endocrine support studies.

Product Overview

Compound: CJC-1295 without DAC
Strength: 20 mg per vial
Injection type: Subcutaneous
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 20 mg
BAC water: 2 mL
Amount per unit: 100 mcg per unit

Research Dose

Protocol dependent.

Notes

CJC-1295 without DAC is commonly described as a modified GHRH analogue used in growth hormone-related research. Unlike CJC-1295 with DAC, the without-DAC version is generally treated as a shorter-acting compound in research contexts.

It has been studied in relation to endogenous growth hormone release, IGF-1 response, pituitary signaling, recovery-related pathways, and body composition research.

No standard consumer dosing protocol should be assumed. Use only within appropriate research or professional guidance frameworks.

Disclaimer

This product is intended for research and informational purposes only.